The prognosis of patients with lymphocytic myocarditis (LM) is poor with the combined endpoint of death or transplant in the Myocarditis Treatment trial being 56% at 5 years. Physicians often have difficulty determining the prognosis in an individual patient. Patients with LM may have ongoing myocardial inflammation. We evaluated the ability of a serum marker of inflammation to predict prognosis in patients with LM. Serum concentrations of C-reactive protein (CRP) were measured in patients with LM. Thiry-one patients with clinical and histologic evidence of LM were evaluated. Patients with coronary artery disease, and idiopathic dilated and secondary cardiomyopathies were excluded. Overall mortality and morbidity from congestive heart failure was assessed at 28 days. The mean plasma CRP concentrations in the five patients who died within the 28-day follow-up period were significantly higher than in those patients who survived (17.4 ± 5.6 vs 5.9 ± 3.3 mg/ml, p < 0.05). The CRP concentration was positively correlated with plasma levels of lactic dehydrogenase and the New York Heart Association functional class. Routine measurement of CRP may be a useful tool for determining the prognosis in patients with LM. (Jpn Heart J 2000 ; 41 : 41-47) 
L YMMPHOCYTIC myocarditis (LM) is the most common type of myocarditis worldwide.
1) The clinical course of patients with LM is variable and their prognosis is unpredictable. Some patients have excellent long-term survival, whereas others have refractory congestive heart failure and early mortality.
2) It has been difficult for the physician to reliably predict the outcome in an individual patient. While laboratory tests such as cardiac troponin-I have been identified in previous studies as a useful marker of myocyte injury in patients with LM, 3) its utility in management of LM is unclear. A proportion of patients with LM may have ongoing myocardial damage secondary to viral or immune-mediated myocardial inflammation. Prognostic determinants were identified as prognostic markers, but these factors were not correlated with an index of host inflammation. To develop an objective method to assess inflammation in LM, we measured plasma concentrations of C-reactive protein (CRP), a precise objective index of inflammatory activity. 4) Assays for CRP are widely available assays used for clinical measurements 5) and permit the noninvasive detection of low-grade inflammation.
Viral infections are the most common cause of LM, with the enteroviruses, especially coxsackie B, representing the most common pathogen in humans. 6) Inflammatory infiltrates can persist long after infectious viral particles disappear. The cause of continued inflammation and myocardial damage may be humoral or cell-mediated immune reactions against viral antigens, self-antigens or crossreactive antigens. 7) However, a prognostic indicator based on inflammation has yet to be defined in patients with LM. To determine the prognostic significance of CRP in patients with LM, we evaluated the ability of CRP measurements on admission to predict the 28-day mortality in addition to routine laboratory data and physical examination.
METHODS
Patient selection: Thirty-one patients with clinical features and endomyocardial biopsies diagnostic of LM at the Second Department of Internal Medicine at Gunma University Hospital and its affiliated hospitals were evaluated from 1988 to 1997. All patients had clinical features such as chest pain, dyspnea, palpitation or flue-like symptoms characterized by fever, malaise, sore throat, and cough. Eleven patients were diagnosed as having enteroviral myocarditis by a four-fold increase in antiviral titer. Coxsackie B virus was implicated serologically in 8 patients, Coxsackie A in 1 and echovirus in 2. In addition, endomyocardial biopsy specimens were obtained and diagnosed as LM. There were 17 men and 14 women, ranging in age from 5 to 74 years (mean 38.3 years). Patients with coronary heart disease, idiopathic dilated and secondary cardiomyopathies were excluded. The clinical, electrocardiographic, and echocardiographic data are shown in Table I . Definition of lymphocytic myocarditis: The diagnosis of lymphocytic myocarditis was based on histologic evidence of inflammatory cell infiltrates with myocyte necrosis. Laboratory study: Blood samples were taken from patients on admission. The following serum concentrations were measured: total protein, aspartate transpeptidase (AST), alanine transpeptidase (ALT), lactate dehydrogenase (LDH), γ-glutamine transferase γ-GTP), direct bilirubin, alkali phosphatase (ALP), creatine phosphokinase (CPK), blood urea nitrogen (BUN), creatinine, blood sugar, electrolytes, white blood cell number, and hemoglobin. Statistical analysis: Statistical comparisons of the baseline characteristics and clinical outcomes were performed using the chi-square test, student t-test and linear regression analysis.
RESULTS

Routine laboratory examination:
The clinical features are shown in Table I . The left ventricular ejection fraction was significantly lower (p < 0.05) in patients with a poor LM outcome than in surviving patients (Table I) . The total protein, serum enzymes and other laboratory data on admission were not statistically different between the patients who survived and those who died (Table II) . C-reactive protein concentrations: The circulating concentrations of CRP in patients with LM were variable. The mean plasma CRP concentrations in the five patients who died within the 28-day follow-up period were significantly higher than those in surviving patients (17.4 ± 5.6 vs 5.9 ± 3.3 mg / dl, p < 0.05, Figure  1 ). Plasma CRP in 20 normal volunteers was less than 2 mg / dl. Correlations between CRP and clinical findings: The plasma CRP concentrations in patients with LM showed a slightly negative, although not statistically significant, correlation with respect to left ventricular ejection fraction The correlation between CRP concentration and plasma CPK concentration was not statistically significant (r = 0.11, p = 0.09), however, plasma LDH concentration and the New York Heart Association Functional Class (NYHA) were positively correlated with CRP concentration (LDH; r = 0.45, p < 0.05, NYHA; r = 0.68, p < 0.0001) (Figure 2 ).
DISCUSSION
The present study demonstrates that serum CRP concentration on admission was markedly higher in died patients with LM who died compared with survivors. The increased inflammatory reaction seems to be associated with a poor prognosis for LM. Since plasma LDH concentration and the NYHA were positively correlated with CRP concentration, higher levels of CRP concentration may indicate a poor outcome in patients with LM.
Several studies have examined CRP concentrations in coronary diseases. Both coronary artery disease and LM can induce congestive heart failure and myocardial damage. CRP is an inflammatory protein whose production is stimulated by a number of different cytokines, including interleukin-6, tumor necrosis factor-α, and interleukin-1. These cytokines are released from the monocytes / macrophages activated by myocardial ischema or inflammation.
10)
The presence of myocardial inflammation in LM is well documented, and inflammatory cytokines have been shown to be investigated in patients with LM. 11) Long-term studies of patients with clinically suspected and biopsy-proven myocarditis reveal a subgroup of dilated cardiomyopathy (approximately 12%) which progresses to chronic dilated cardiomyopathy. 11) Later in the course of experimental murine myocarditis, a dilated cardiomyopathy develops which is indistinguishable from the dilated cardiomyopathy in humans.
12) Therefore, it is possible that inflammation present in viral or other types of myocarditis may induce advanced myocardial damage which produces severe heart failure and poor prognosis.
Other variables have been reported as significant prognostic factors in 2) Right ventricular systolic dysfunction is associated with an adverse outcome when compared to myocarditis patients with normal RV function. 13) In general, light microscopic biopsy findings do not predict outcome. In our study, routine measurement of CRP is also suggested to be an important indicator of clinical severity in patients with LM and the CRP is independent from other markers of heart failure such as left ventricular ejection fraction.
Anti-inflammatory agents, such as prednisolone do not prolong survival in patients with LM.
2) In a clinical trial of interferon-α (IFN-α), however, left ventricular function, exercise tolerance and the survival rate were significantly better in long-term follow-up in patients treated with IFN-α compared to conventional treatment. 14) Additionally, immunomodulatory therapy with immunoglobulin improved LV function in patients with acute LM. 15) Since immunomodulatory therapy may decrease myocyte inflammation, CRP may be a useful marker to select in patients with LM who have a poor prognosis and who might benefit from immunomodulatory therapy. We believe that the serum CRP concentration should be measured routinely in patients suspected of having LM as well as during routine physiological examination. The CRP concentration is a useful guide to therapy and an index of the prognosis in myocardial inflammation.
